Phase 3 INTerpath-009 Trial of mRNA-4157 Plus Pembrolizumab for NSCLC Begins Recruitment | Docwire News
The pivotal phase 3 INTerpath-009 trial has begun global recruitment of patients with resectable non-small cell lung cancer, according to Merck and Moderna.